Cargando…
The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
SIMPLE SUMMARY: Considering recent research, it was established that the best experimental models to conserve biological features of human tumors and to predict individual clinical treatment success are patient-derived xenografts (PDX). Their recognized and growing importance for translational resea...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656526/ https://www.ncbi.nlm.nih.gov/pubmed/34884989 http://dx.doi.org/10.3390/cancers13235882 |
_version_ | 1784612302246379520 |
---|---|
author | Matschos, Stephanie Bürtin, Florian Kdimati, Said Radefeldt, Mandy Krake, Susann Prall, Friedrich Engel, Nadja Krohn, Mathias Micheel, Bianca Kreutzer, Michael Mullins, Christina Susanne Linnebacher, Michael |
author_facet | Matschos, Stephanie Bürtin, Florian Kdimati, Said Radefeldt, Mandy Krake, Susann Prall, Friedrich Engel, Nadja Krohn, Mathias Micheel, Bianca Kreutzer, Michael Mullins, Christina Susanne Linnebacher, Michael |
author_sort | Matschos, Stephanie |
collection | PubMed |
description | SIMPLE SUMMARY: Considering recent research, it was established that the best experimental models to conserve biological features of human tumors and to predict individual clinical treatment success are patient-derived xenografts (PDX). Their recognized and growing importance for translational research, especially for late-stage preclinical testing of novel therapeutics, necessitates a high number of well-defined PDX models from individual patients’ tumors. The starting platform for the Hansestadt Rostock colorectal cancer (HROC)-Xenobank was the assortment of colorectal tumor and normal tissue samples from patients stored in our university biobank. ABSTRACT: Based on our research group’s large biobank of colorectal cancers (CRC), we here describe the ongoing activity of establishing a high quality assured PDX biobank for more than 100 individual CRC cases. This includes sufficient numbers of vitally frozen (n > 30 aliquots) and snap frozen (n > 5) backups, “ready to use”. Additionally, PDX tumor pieces were paraffin embedded. At the current time, we have completed 125 cases. This resource allows histopathological examinations, molecular characterizations, and gene expression analysis. Due to its size, different issues of interest can be addressed. Most importantly, the application of low-passage, cryopreserved, and well-characterized PDX for in vivo studies guarantees the reliability of results due to the largely preserved tumor microenvironment. All cases described were molecularly subtyped and genetic identity, in comparison to the original tumor tissue, was confirmed by fingerprint analysis. The latter excludes ambiguity errors between the PDX and the original patient tumor. A cancer hot spot mutation analysis was performed for n = 113 of the 125 cases entities. All relevant CRC molecular subtypes identified so far are represented in the Hansestadt Rostock CRC (HROC)-Xenobank. Notably, all models are available for cooperative research approaches. |
format | Online Article Text |
id | pubmed-8656526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86565262021-12-10 The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models Matschos, Stephanie Bürtin, Florian Kdimati, Said Radefeldt, Mandy Krake, Susann Prall, Friedrich Engel, Nadja Krohn, Mathias Micheel, Bianca Kreutzer, Michael Mullins, Christina Susanne Linnebacher, Michael Cancers (Basel) Article SIMPLE SUMMARY: Considering recent research, it was established that the best experimental models to conserve biological features of human tumors and to predict individual clinical treatment success are patient-derived xenografts (PDX). Their recognized and growing importance for translational research, especially for late-stage preclinical testing of novel therapeutics, necessitates a high number of well-defined PDX models from individual patients’ tumors. The starting platform for the Hansestadt Rostock colorectal cancer (HROC)-Xenobank was the assortment of colorectal tumor and normal tissue samples from patients stored in our university biobank. ABSTRACT: Based on our research group’s large biobank of colorectal cancers (CRC), we here describe the ongoing activity of establishing a high quality assured PDX biobank for more than 100 individual CRC cases. This includes sufficient numbers of vitally frozen (n > 30 aliquots) and snap frozen (n > 5) backups, “ready to use”. Additionally, PDX tumor pieces were paraffin embedded. At the current time, we have completed 125 cases. This resource allows histopathological examinations, molecular characterizations, and gene expression analysis. Due to its size, different issues of interest can be addressed. Most importantly, the application of low-passage, cryopreserved, and well-characterized PDX for in vivo studies guarantees the reliability of results due to the largely preserved tumor microenvironment. All cases described were molecularly subtyped and genetic identity, in comparison to the original tumor tissue, was confirmed by fingerprint analysis. The latter excludes ambiguity errors between the PDX and the original patient tumor. A cancer hot spot mutation analysis was performed for n = 113 of the 125 cases entities. All relevant CRC molecular subtypes identified so far are represented in the Hansestadt Rostock CRC (HROC)-Xenobank. Notably, all models are available for cooperative research approaches. MDPI 2021-11-23 /pmc/articles/PMC8656526/ /pubmed/34884989 http://dx.doi.org/10.3390/cancers13235882 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Matschos, Stephanie Bürtin, Florian Kdimati, Said Radefeldt, Mandy Krake, Susann Prall, Friedrich Engel, Nadja Krohn, Mathias Micheel, Bianca Kreutzer, Michael Mullins, Christina Susanne Linnebacher, Michael The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models |
title | The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models |
title_full | The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models |
title_fullStr | The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models |
title_full_unstemmed | The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models |
title_short | The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models |
title_sort | hroc-xenobank—a high quality assured pdx biobank of >100 individual colorectal cancer models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656526/ https://www.ncbi.nlm.nih.gov/pubmed/34884989 http://dx.doi.org/10.3390/cancers13235882 |
work_keys_str_mv | AT matschosstephanie thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT burtinflorian thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT kdimatisaid thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT radefeldtmandy thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT krakesusann thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT prallfriedrich thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT engelnadja thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT krohnmathias thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT micheelbianca thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT kreutzermichael thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT mullinschristinasusanne thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT linnebachermichael thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT matschosstephanie hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT burtinflorian hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT kdimatisaid hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT radefeldtmandy hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT krakesusann hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT prallfriedrich hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT engelnadja hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT krohnmathias hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT micheelbianca hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT kreutzermichael hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT mullinschristinasusanne hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels AT linnebachermichael hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels |